Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

Recruiting now · Phase 3

Conditions studied: Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases

In brief

This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily \[both dose adjusted per Food and Drug Administration (FDA) label\] for 200 days post-transplant), or PET (central lab weekly plasma polymerase chain reaction (PCR) monitoring for CMV deoxyribonucleic acidemia (DNAemia)) for 100 days post-transplant, with oral valganciclovir 900mg orally twice daily (or renally dosed per FDA label) at onset of CMV DNAemia at any level and continued until plasma CMV DNAemia is negative or below the level of quantitation in two consecutive weekly plasma samples. Study participants will be followed for pre-specified outcomes (clinical, laboratory, immunologic, safety) until withdrawal, death, or study closure, up to a maximum of 5.5 years post-transplant. Approximately 360 participants (180 participants in each group) will be randomized into the study. Estimated Time to Complete Enrollment: 4 years

Key facts

Study ID: NCT06798909
Run by: University of California, San Francisco
People needed: 360
Starts: 2025-07-22
Expected to finish: 2031-05-31
Last updated by the study team: 2026-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subject or legally authorized representative has provided written informed consent.
Age ≥ 18 years of age at the time of informed consent.
Negative for IgG antibody to CMV as assessed in a CLIA-certified laboratory between 28 days prior to transplant and up to 7 days post-transplant but prior to randomization.
Received a kidney transplant from a CMV seropositive (IgG positive) donor in the past 7 days prior to enrollment
Individuals of reproductive (childbearing) potential must have a negative pregnancy test (serum or urine) collected prior to randomization (SOC results within 7 days prior to transplant may be used), and must also agree to use a medically approved method of contraception. Acceptable methods include: barrier method, intrauterine device (hormonal or non-hormonal), oral hormonal contraceptives, abstinence from the time of enrollment through until discontinuation of ganciclovir or valganciclovir in either arm during the intervention period.
NOTE: Individuals of reproductive potential are defined as individuals who have reached menarche and who have not been post-menopausal for at least 12 consecutive months with follicle stimulating hormone (FSH) ≥40 IU/mL or 24 consecutive months if an FSH is not available, i.e., who have had menses within the preceding 24 months, and have not undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, or salpingectomy).
If male, must agree to practice a barrier method of contraception or abstinence from the time of enrollment through 3 months after discontinuation of ganciclovir or valganciclovir in either arm during the intervention period.

You may not qualify if…

In the opinion of the investigator, participants who are unable or unwilling to undergo preemptive therapy protocol (weekly CMV PCR, etc.)
Patients who are breastfeeding or planning to breastfeed within 6 months post-transplant
Allergy to valganciclovir/ganciclovir or Letermovir
Receipt of immunoglobulin or CMV-specific immunoglobulin within the last 3 months (this includes COVID convalescent plasma)
Currently enrolled or anticipated enrollment in another interventional study that, in the opinion of scientific leadership team, could affect evaluation of the primary safety and/or efficacy outcomes.
Most recent platelet count post-transplant <25,000/uL
Most recent ANC performed post-transplant <1000/uL
Multi-organ transplant (except simultaneous kidney-pancreas) within the past 7 days
Prior or planned receipt of a hematopoietic cell transplant
Baseline immunodeficiency prior to transplant, including but not limited to:
Known or suspected HIV infection
Congenital or acquired immunodeficiency
Unacceptable immunosuppression
Receipt of desensitization therapy prior to kidney transplant, or
Receipt of an ABO-incompatible kidney transplant except A2 to blood type B

Where it is running

University of California, San Francisco School of Medicine — San Francisco, California, United States (enrolling)
University of Miami Miller School of Medicine — Miami, Florida, United States (enrolling)
Emory University School of Medicine — Atlanta, Georgia, United States (enrolling)
Robert Wood Johnson Health Network Barnabas Health — Livingston, New Jersey, United States (enrolling)
Medical College of Virginia Commonwealth — Richmond, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.